STOCK TITAN

Medicus Pharma Ltd. (MDCX) S-1 Filings

MDCX NASDAQ

Here are the S-1 registration statements from Medicus Pharma Ltd. (MDCX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-1 covers the registration statement a company files to sell shares publicly, so if you follow MDCX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDCX filings page.

Rhea-AI Summary

Medicus Pharma Ltd. is registering up to 2,680,000 common shares for resale by Armistice Capital Master Fund Ltd. These shares are issuable upon exercise of 2,680,000 Private Warrants with a $3.75 exercise price and a July 15, 2030 expiry. Medicus is not selling shares itself and will not receive proceeds from any resale, though it may receive up to $10,050,000 if the Private Warrants are exercised.

The company is a clinical-stage life sciences business developing SkinJect™, a dissolvable microneedle patch for basal cell carcinoma, and Teverelix for high‑risk prostate cancer and acute urinary retention. It recently acquired 98.6% of Antev Limited to advance Teverelix and has begun Phase 2 SkinJect™ trials and regulatory initiatives in the U.S. and U.K.

Medicus remains deeply loss‑making, with a net loss of $27.3 million for the nine months ended September 30, 2025 and an accumulated deficit of about $56.2 million, resulting in a shareholders’ deficit and an auditor‑flagged substantial doubt about its ability to continue as a going concern. The company expects to need significant additional financing, faces extensive regulatory and clinical risk, and relies heavily on key licenses and successful integration of Antev. Its shares trade on Nasdaq under “MDCX”.

Rhea-AI Summary

Medicus Pharma Ltd. has filed a Form S-1 to register the resale of up to 1,397,184 common shares by existing selling shareholders. These shares are part of the stock consideration issued in the August 2025 acquisition of Antev Limited, a late clinical-stage drug developer focused on the prostate cancer candidate Teverelix.

The company itself is not selling any securities in this offering and will receive no proceeds from any resale. After the offering, Medicus expects to have 21,865,288 common shares outstanding, based on 20,468,104 shares outstanding as of September 22, 2025. Medicus is an emerging growth and smaller reporting company, developing SkinJect for non-melanoma skin cancers and Teverelix for high-risk prostate cancer and acute urinary retention, and it highlights substantial risks, including a going concern warning and an accumulated deficit of about $40.2 million as of June 30, 2025.

Rhea-AI Summary

Medicus Pharma, Inc. (MDCX) filed an S-1 registration including a prospectus structure and partial financial schedules. The filing shows multiple equity issuances during 2024–2025: common shares and warrants were issued under a Regulation A offering with issuance costs of $483,020, and a later equity financing with net offering costs of $809,606. The company records repeated net loss and comprehensive loss for successive periods and reports stock-based compensation expense and share issuances upon warrant exercises. Financing activities include proceeds from common shares and warrants, debentures and convertible notes, with related issuance costs and non-cash adjustments. The cash flow section lists net cash used in operating activities and net cash provided by financing activities, and the balance sheet excerpts reference money market funds and debentures measured at fair value. The filing also discloses operating lease right-of-use assets and liabilities, valuation inputs for warrants/options, and certain redactions under Regulation S-K.